Neilanjan Nandi, MD, FACG, AGAF, FACP
Gastroenterology
Headshot of Neilanjan Nandi, MD, FACG, AGAF, FACP
Make an appointmentCall 800-789-7366

Neilanjan Nandi, MD, FACG, AGAF, FACP

Gastroenterology
Accepting new patients
Sees patients age 18 and up
Penn Digestive and Liver Health Center University City
View 2 additional locations
Make an appointmentCall 800-789-7366
Headshot of Neilanjan Nandi, MD, FACG, AGAF, FACP
Penn Medicine Provider

About me

  • Co-Section Head and Clinical Program Director, Penn Inflammatory Bowel Diseases Program
  • Professor of Clinical Medicine (Gastroenterology)

Dr. Nandi is a Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Clinical Director and Co-Section Lead of the Inflammatory Bowel Disease (IBD) Program the University of Pennsylvania.

Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent Clostridioides difficile infection (C difficile).

After completing residency at Thomas Jefferson and fellowship at the University of Miami, Dr. Nandi developed specialty interest in the diagnosis and management of complex IBD, refractory C. difficile infection and the application of fecal microbiota restoration therapies to these disease states. He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and novel emerging agents in the treatment of IBD.

Through the years, Dr. Nandi has had the privilege of serving on the Philadelphia Crohn's & Colitis Foundation (CCF) Executive Council. In this capacity he has served on numerous CCF health care professional educational programs, has been a Camp Oasis volunteer physician, previously co-chaired the Take Steps for Crohn's & Colitis fundraising campaign and currently serves as co-chair of the Health Professional Education Committee. Dr. Nandi is a founding non-profit board member and Chairman of the Board of Directors for the Strategic Alliance for Intercultural Advocacy (SAIA) which elevates culturally competent care in IBD and other GI illnesses. He also serves on the medical advisory board of the United Ostomy Associates of America (UOAA), and coordinates outreach on the American College of Gastroenterology (ACG) Patient Care Committee.

Dr. Nandi's fervor for clinical education has been recognized with multiple teaching awards throughout his career at the medical school, residency, fellowship and graduate school levels. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley CCF at their annual Take Steps for Crohn's & Colitis event and awarded the 2022 CCF's Chairman's National Citation Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine at the University of Pennsylvania. Dr. Nandi is very blessed to be honored as the 2024 Philadelphia CCF's Gold Medallion Award Physician Honoree. He is also the recipient of the inaugural 2025 SAIA Excellence in Leadership & Advocacy Award.

My education and training

  • Northwestern University Feinberg School of MedicineMedical School
  • Thomas Jefferson University HospitalResidency
  • Jackson Health System - Jackson MemorialFellowship

Spoken languages

English
English

Reviews

Average Rating

576 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
August 2026
he is thorough and in good command of all the data and relevant information. he is pleasant and friendly
Anonymous
August 2026
i felt the md listened and addressed my issues.
Anonymous
August 2026
i have been seeing dr. nandi for years and he is kind, responsive to messages and a really great dr.
Anonymous
July 2026
he is very knowledgeable and caring

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

PRIMARY LOCATION
800-789-7366
Learn about location
215-662-8900
Learn about location
610-902-1500
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Nandi is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Toiv A, Saleh Z, Alsheik E, Venkat D, Nandi N, Zuchelli T. Digesting Digital Health: A study of appropriateness and readability of Chat GPT generated gastroenterological information. , Clinical and Translational Gastroenterology., 15(11:e00765): 2024

Yarur AJ, Long M, Torres J, Nandi N, Cross RK, Abbatemarco AM, Blanco D, Niezychowski W, Crosby C, Wu J, Pradeep G, Goetsch M, Panaccione R. Body mass index does not affect the efficacy and safety of etrasimod in ulcerative colitis patients: a post hoc analysis from the ELEVATE UC clinical program. , American Journal of Gastroenterology., 119(10S): 2024,S1026-S1027

Sehgal P, Khanna T, Profka K, Pickett-Blakely O, Nandi N, Rashid F, Bewtra M, Lewis J, Lichtenstein G, Aberra F. Safety and clinical effectiveness of GLP1 agonists in inflammatory bowel disease patients. , Clin Gastroenterol Hepatol, 25: 2025,S1542-3565(25)00073-4.

Sehgal P, Khanna T, Profka K, Pickett-Blakely O, Nandi N, Rashid F, Bewtra M, Lewis J, Lichtenstein G, Aberra F. Impact of GLP1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease. , DDW, Poster Sa1950: 2024

Brittaney Bonhomme, BS, Neilanjan Nandi, MD,†, Shivali Berera, MD, Helen Lee, MD, Galen Leung, MD, Chung SangTse, MD, Alexandra Weiss, MD, Lisa Nessel, MSS, MLSP, Yue Ren, MA, Hongzhe Li, PhD, Faten N. Aberra, MD, MSCE, James D. Lewis, MD, MSCE Greater Fatigue and Reduced Neurocognitive Speed With Symptomatic Crohn’s Disease. , Crohn's & Colitis 360, 7(1): 2024,1-12

Elias S, Nandi N, Grover L, Fourie S, Newman KL Addressing Factors that Impact Sexual Well-Being and Intimacy in IBD Patients , Curr Gastroenterol Rep: 2025,1-10

Tina Aswani-Omprakash, Jalpa Devi, Madhura Balasubramaniam, Ashwin N. Ananthakrishnan, Neilanjan Nandi, Parakkal Deepak, Shaji Sebastian, Sumit Bhatia, Smruti Govan, Vishal Sharma, Kiran Peddi, Tauseef Ali, Reezwana Chowdhury. Patient-Inclusive Recruitment in Inflammatory Bowel Disease Trials: Key Takeaways From the 2025 Strategic Alliance for Intercultural Advocacy in GI-American Gastroenterological Association Asian Clinical Research Roundtable , Clinical Gastroenterology & Hepatology, 24(5): 2026,1209-1214

Allison Ferris, Polina Gaisinskaya, Neilanjan Nandi. Approach to Diarrhea. , Primary Care: Clinics in Office Practice: 2023,447-459

Charan V, Mukherjee S, Nandi N, Weiss A, Schmoyer C. Evaluating AI-Language models in providing answers for inflammatory bowel disease (IBD) in pregnancy: A comparative analysis of GPT4, BARD and LLAMA2. , DDW, Poster Mo1883: 2024

Balasubramaniam M, Nandi N, Aswani-Omprakash T, Sebastian S, Sharma V, Deepak P; South Asian Ibd Alliance Board Of Directors. Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia , Gastroenterology, 163(5): 2022,1145-1150